Cargando…
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
German Medical Science GMS Publishing House
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118693/ https://www.ncbi.nlm.nih.gov/pubmed/21698087 http://dx.doi.org/10.3205/000134 |
| _version_ | 1782206496028753920 |
|---|---|
| author | Patrij, Katrin Reiser, Marcel Wätzel, Luise Pels, Hendrik Kowoll, Annika Herrlinger, Ulrich Engert, Andreas Linnebank, Michael Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. |
| author_facet | Patrij, Katrin Reiser, Marcel Wätzel, Luise Pels, Hendrik Kowoll, Annika Herrlinger, Ulrich Engert, Andreas Linnebank, Michael Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. |
| author_sort | Patrij, Katrin |
| collection | PubMed |
| description | We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL). |
| format | Online Article Text |
| id | pubmed-3118693 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | German Medical Science GMS Publishing House |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-31186932011-06-22 Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis Patrij, Katrin Reiser, Marcel Wätzel, Luise Pels, Hendrik Kowoll, Annika Herrlinger, Ulrich Engert, Andreas Linnebank, Michael Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. Ger Med Sci Article We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL). German Medical Science GMS Publishing House 2011-05-02 /pmc/articles/PMC3118693/ /pubmed/21698087 http://dx.doi.org/10.3205/000134 Text en Copyright © 2011 Patrij et al. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free to copy, distribute and transmit the work, provided the original author and source are credited. |
| spellingShingle | Article Patrij, Katrin Reiser, Marcel Wätzel, Luise Pels, Hendrik Kowoll, Annika Herrlinger, Ulrich Engert, Andreas Linnebank, Michael Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_full | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_fullStr | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_full_unstemmed | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_short | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_sort | isolated central nervous system relapse of systemic lymphoma (scnsl): clinical features and outcome of a retrospective analysis |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118693/ https://www.ncbi.nlm.nih.gov/pubmed/21698087 http://dx.doi.org/10.3205/000134 |
| work_keys_str_mv | AT patrijkatrin isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT reisermarcel isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT watzelluise isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT pelshendrik isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT kowollannika isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT herrlingerulrich isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT engertandreas isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT linnebankmichael isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT schackertgabriele isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT vogtschadenmarlies isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT egerergerlinde isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT lamprechtmonika isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT batchelortracyt isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT schlegeluwe isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT schmidtwolfingogh isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis |